News | February 14, 2008

Sorin Launches U.S. Trial on Semirigid Annuloplasty Ring

February 15, 2008 - The Sorin Group is launching the Sorin MEMO 3D Annuloplasty Ring for mitral valve repair clinical trial at Penn Presbyterian Medical Center, which is designed to evaluate the effectiveness and safety of MEMO 3D for diseased or dysfunctional mitral valve repair.

The MEMO 3D when used to repair a diseased or dysfunctional mitral valve. The open label, multisite, treatment study will be recruiting patients and will be conducted at Penn Presbyterian Medical Center and several other North American sites. The primary outcome measure of the study will be the percentage of patients with successful repair at six months. Secondary outcome measures are: freedom from re-operation at 12 months; preoperative and postoperative mitral valve regurgitation, left ventricular dimensions and mass assessed by echocardiography; actuarial survival and freedom from clinical events at 12 months.

The lead principal investigator for the clinical trial is Dr. W. Clark Hargrove, III, M.D., clinical professor of surgery at the University of Pennsylvania School of Medicine and Clinical Director, Division of Cardiovascular Surgery, Penn Presbyterian Medical Center.

“We are looking forward to learning more about how the device’s flexible capabilities will impact its efficacy in functional, ischemic and degenerative Mitral Regurgitation (MR) as well as rheumatic procedures,” said Dr. Hargrove. “The device’s design makes it relatively easy to implant in place, and there is potential that it may be able to be used in many disease processes.”

Researchers hope the ring results in better physiological motion of the mitral annulus after mitral valve repair due to its flexible design and the Carbofilm coating of the ring. This results in decreased inflammatory response due to the introduction of a foreign body into the bloodstream.

For more information: www.clinicaltrials.gov and www.sorin.com

Related Content

HAART 300 Aortic Annuloplasty Device Sees U.S. Pilot Launch, First Commercial Use
News | Annuloplasty Rings| July 05, 2017
July 5, 2017 — BioStable Science & Engineering Inc.
Sponsored Content | Videos | Heart Valve Technology| January 03, 2017
This video, provided by Valtech, demonstrates the Cardioband transcatheter mitral annuloplasty system.
TITAN II Trial, Carillon Mitral Contour System, Cardiac Dimensions, Open Heart journal, functional mitral regurgitation, FMR
News | Annuloplasty Rings| July 20, 2016
New data from the TITAN II trial confirm the safety and efficacy of the Carillon Mitral Contour System in the treatment...
Mitralign Percutaneous Annuloplasty System, MPAS, CE Mark approval
News | Annuloplasty Rings| April 27, 2016
Mitralign Inc. announced its Mitralign Percutaneous Annuloplasty System (MPAS) has received CE mark approval from its...
Carillon mitral contour system, Cardiac Dimensions, functional mitral regurgitation, FMR, University Hospital Liepzig study
News | Annuloplasty Rings| February 24, 2016
A single-center study noted that treatment with Cardiac Dimensions’ Carillon Mitral Contour System resulted in...
Carillon mitral contour system, cost-effective, optimal medical treatment, OMT, TITAN, functional mitral regurgitation, FMR

Carillon mitral contour system image courtesy of Cardiac Dimensions Inc.

News | Annuloplasty Rings| September 10, 2015
The Carillon mitral contour system is projected to be a cost-effective treatment option when compared to a typical...
Valtech, cardioband, transcatheter mitral annuloplasty

Valtech's Cardioband transcatheter mitral annuloplasty system in development. It is uses a series of corkscrew anchors, similar to those used on EP implantable device leads, to install the annuloplasty ring to reshape the valve for improved leaflet coaptation.

Feature | Structural Heart| September 02, 2015
September 2, 2015 — HeartWare International Inc.
Mitralign, Percutaneous Tricuspid Valve Annuloplasty System

Mitralign's Percutaneous Tricuspid Valve Annuloplasty System uses catheter delivered pledgeted sutures that can be cinched together to change the valve annulus geometry to help eliminate valvular regurgitation. 

News | Heart Valve Technology| August 31, 2015
August 31, 2015 — Mitralign Inc. said the U.S.
Mitralign, six-month data, EuroPCR 2015, MPAS

Image courtesy of Mitralign.

Feature | June 01, 2015
Mitralign shared six-month data on its Mitralign Percutaneous Annuloplasty System (MPAS) for treatment of functional...
Overlay Init